Neogenomics IncChange company Symbol lookupSelect an option...NEO Neogenomics IncSYBX Synlogic IncNEOV NeoVolta IncFIISO Financial Institutions IncKA Kineta IncTCS Container Store Group IncMLGO MicroAlgo IncINDI indie Semiconductor IncJCI Johnson Controls International PLCFPAY FlexShopper IncGo
Change company Symbol lookup
Select an option...
NEO Neogenomics Inc
SYBX Synlogic Inc
NEOV NeoVolta Inc
FIISO Financial Institutions Inc
KA Kineta Inc
TCS Container Store Group Inc
MLGO MicroAlgo Inc
INDI indie Semiconductor Inc
JCI Johnson Controls International PLC
FPAY FlexShopper Inc
Health Care : Health Care Providers & Services | Small Cap Blend
Company profileNeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: Clinical Services, and Advanced Diagnostics. The Clinical Services segment provides various clinical-testing services related to oncology diagnostics, community-based oncology and pathology sales, patient engagement, and clinical decision support. The Clinical Services segment also offers Trapelo, a decision-making informatics tool, to help health care professionals navigate the rapidly evolving field of precision medicine. The Advanced Diagnostics segment includes pharma services, informatics, research and development, and minimal residual disease, liquid biopsy and therapy selection business development. Additional offerings within the Advanced Diagnostics portfolio include Informatics, which involves the licensing of de-identified data to pharmaceutical and biotech customers in the form of either retrospective records or prospective deliveries of data.
|
|
|
|
| |
| Latest Earnings (Q2 ending 06/2023) | Upcoming Announcement (Q3 ending 09/2023) | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. | -$0.05 | Estimate increased in year leading up to announcement | 0.80% | Q3 consensus estimate | -$0.08 | Q3 consensus estimate is higher than previous yr's Q3 actual | 41.43% |
| Q2 Consensus estimate | -$0.11 | Previous year's Q3 actual | -$0.14 | ||||
Quarterly Consensus Estimate Trends over Time
NEO's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.